# US 2024/0254144 A1 · Salt form of pyrrolotriazine compound, crystal form thereof, and preparation method therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0254144 A1
- Document ID: US20240254144A1
- Status: Published application
- Kind: A1
- Application number: 18/558,731
- Filed: 2022-05-07
- Published: 2024-08-01
- Earliest claimed: 2021-05-08
- Assignees: Jumbo Drug Bank Co., Ltd.
- Applicants: Jumbo Drug Bank Co., Ltd.
- Inventors: Lingyun WU; Xiawei WEI; Xu YOU; Xiongbin XU; Ning JIANG; Shuhui CHEN
- Web page: https://patentgrep.com/patent/US20240254144A1

## CPC

- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495})
- A61P 35/00: Antineoplastic agents
- C07C 309/30: of six-membered aromatic rings substituted by alkyl groups
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A pyrrolotriazine compound, e.g., the compound of formula (II), a salt form thereof, a crystal form thereof, a preparation method therefor, and an application thereof are provided. An application in preparation of MNK1/2 inhibitor drugs and/or in preparation of drugs for treating colorectal cancer are also provided.

## Claims

### Claim 1

A compound of formula (II),

### Claim 2

Crystal form A of a compound of formula (II), wherein an X-ray powder diffraction pattern of the crystal form A comprises characteristic diffraction peaks at the following 2θ angles: 7.78±0.20°, 11.38±0.20°, and 20.58±0.20°;

### Claim 3 (depends on 2)

The crystal form A according to claim 2, wherein the X-ray powder diffraction pattern of the crystal form A comprises characteristic diffraction peaks at the following 2θ angles: 7.78±0.20°, 9.44±0.20°, 11.38±0.20°, 19.84±0.20°, 20.58±0.20°, 21.56±0.20°, 22.86±0.20°, and 24.82±0.20°.

### Claim 4 (depends on 3)

The crystal form A according to claim 3, wherein the X-ray powder diffraction pattern of the crystal form A comprises characteristic diffraction peaks at the following 2θ angles: 6.58±0.20°, 7.78±0.20°, 9.44±0.20°, 11.38±0.20°, 14.38±0.20°, 18.66±0.20°, 19.84±0.20°, 20.58±0.20°, 21.56±0.20°, 22.86±0.20°, 23.54±0.20°, and 24.82±0.20°.

### Claim 5 (depends on 4)

The crystal form A according to claim 4, wherein the X-ray powder diffraction pattern of the crystal form A comprises characteristic diffraction peaks at the following 2θ angles: 4.78°, 6.58°, 7.78°, 9.44° 11.38°, 13.48°, 14.38°, 14.80°, 16.42°, 17.00°, 17.32°, 18.34°, 18.66°, 19.08°, 19.60°, 19.84°, 20.28°, 20.58°, 21.56°, 21.84°, 22.52°, 22.86°, 23.26°, 23.54°, 24.46°, 24.82°, 25.50°, 26.04°, 26.58°, 27.42°, 27.82°, 28.07°, 28.42°, 29.08°, 29.66°, 30.08°, 31.20°, 31.42°, 38.22°, and 39.04°.

### Claim 6 (depends on 5)

The crystal form A according to claim 5, wherein the XRPD pattern of the crystal form A is substantially as shown in FIG. 1.

### Claim 7 (depends on 2)

The crystal form A according to claim 2, wherein a differential scanning calorimetry curve of the crystal form A has an endothermic peak at 287.17±3° C.

### Claim 8 (depends on 7)

The crystal form A according to claim 7, wherein a DSC profile of the crystal form A is shown in FIG. 2.

### Claim 9 (depends on 2)

The crystal form A according to claim 2, wherein a thermogravimetric analysis curve of the crystal form A shows a weight loss of 0.075% at 200.0±3° C.

### Claim 10 (depends on 9)

The crystal form A according to claim 9, wherein a TGA profile of the crystal form A is shown in FIG. 3.

### Claim 11 (depends on 2)

A preparation method for crystal form A of the compound of formula (II) according to claim 2, comprising the following steps:
(a) adding the compound of formula (II) to a solvent to form a suspension;
(b) stirring the suspension at 40-55° C. for 2-25 h; and
(c) filtering the suspension and then drying the filter cake in vacuum at 30-45° C. for 10-24 h; wherein the solvent is selected from methanol, acetonitrile, and tert-butyl methyl ether.

### Claim 12

Crystal form B of a compound of formula (II), wherein an X-ray powder diffraction pattern of the crystal form B comprises characteristic diffraction peaks at the following 2θ angles: 7.55±0.20°, 15.13±0.20°, and 19.82±0.20°;

### Claim 13 (depends on 12)

The crystal form B according to claim 12, wherein the X-ray powder diffraction pattern of the crystal form B comprises characteristic diffraction peaks at the following 2θ angles: 6.89±0.20°, 7.55±0.20°, 9.50±0.20°, 11.35±0.20°, 12.72±0.20°, 15.13±0.20°, 19.82±0.20°, and 26.63±0.20°.

### Claim 14 (depends on 13)

The crystal form B according to claim 13, wherein the X-ray powder diffraction pattern of the crystal form B comprises characteristic diffraction peaks at the following 2θ angles: 6.89±0.20°, 7.55±0.20°, 9.50±0.20°, 11.35±0.20°, 12.24±0.20°, 12.72±0.20°, 15.13±0.20°, 18.94±0.20°, 19.82±0.20°, 23.25±0.20°, 26.63±0.20°, and 27.27±0.20°.

### Claim 15 (depends on 14)

The crystal form B according to claim 14, wherein the X-ray powder diffraction pattern of the crystal form B comprises characteristic diffraction peaks at the following 2θ angles: 4.98°, 6.89°, 7.55°, 8.46°, 9.50°, 10.12°, 11.35°, 12.24°, 12.72°, 14.05°, 15.13°, 15.65°, 16.20°, 17.79°, 18.94°, 19.82°, 20.76°, 21.61°, 23.25°, 23.87°, 26.09°, 26.63°, 27.27°, 28.45°, 29.12°, 30.95°, 32.32°, 34.62°, and 38.41°.

### Claim 16 (depends on 15)

The crystal form B according to claim 15, wherein the XRPD pattern of the crystal form B is substantially as shown in FIG. 4.

### Claim 17 (depends on 12)

The crystal form B according to claim 12, wherein a differential scanning calorimetry curve of the crystal form B has an endothermic peak at 300.0±3° C.

### Claim 18 (depends on 17)

The crystal form B according to claim 17, wherein a DSC profile of the crystal form B is shown in FIG. 5.

### Claim 19 (depends on 2)

A method for inhibiting MNK1/2, which comprises administering to a subject a therapeutically effective amount of the crystal form A according to claim 2.

### Claim 20 (depends on 2)

A method for treating colorectal cancer, which comprises administering to a subject a therapeutically effective amount of the crystal form A according to claim 2.
